Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

>.  

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "goal", "should", "would", "project", "plan", "predict", "intend" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 Best Sanitizers, Inc., the first ... hand sanitizer, asks food processors and food handling professionals ... sanitizer they’re currently using to Best Sanitizers’ Alpet® ... critical to fighting cross-contamination and the spread of pathogens ... there are key criteria that make a hand sanitizer ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... new market research report is ... Whole Exome Sequencing Market ... Preparation, Target Enrichment), by Services ... Synthesis), by Application (Cancer, Monogenic ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Sterlitech is ... polymeric membranes to its stable of products . ... molecular weight cut-offs and include membrane filters with surface ... increase in customer demand for our membrane process testing ... variety of flat sheet membranes,” explains Sterlitech President Mark ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 A ... around the world is available from Strategic Consulting, ... companies. “ Industrial Microbiology Market Review, Fourth Edition: ... Market ” (IMMR—4) tracks and compares microbiology test ... North America, Europe and Asia, and forecasts future ...
Breaking Biology Technology:Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13Sterlitech Corporation Enhances Its Selection of Flat Sheet Membrane Filters 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3
... palm plantations will worsen the dual environmental crises of ... protected, warn scientists in the most comprehensive review of ... from the Zoological Society of London and University of ... the role of palm oil production in tropical deforestation ...
... Micromet, Inc.,(Nasdaq: MITI ) ("Micromet" or ... for the treatment of cancer,inflammation and autoimmune diseases, ... board of directors appointed Dr. Peter Johann, a,current ... member of the Company,s,audit committee. The appointment fills ...
... 15 Inverness Medical,Innovations, Inc. (Amex: IMA ), ... solutions, today declared a,dividend of $4.77 per share on ... dividend will be paid in shares of Series B,stock ... of (a) $4.77 divided by,(b) 97% of the average ...
Cached Biology Technology:Oil palm plantations are no substitute for tropical rainforests, a new study shows 2Oil palm plantations are no substitute for tropical rainforests, a new study shows 3Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule 2Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule 3Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule 4Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock 2
(Date:8/31/2014)... new study of satellite data from the last 19 years ... sea-level around the coast of Antarctica to rise by 2cm ... the University of Southampton detected the rapid rise in sea-level ... than a million square kilometres. , The melting ... ice shelves has contributed an excess of around 350 gigatonnes ...
(Date:8/31/2014)... Over the past several decades, malaria diagnosis has changed very ... technician smears the blood across a glass slide, stains it ... the Plasmodium parasite, which causes the disease. This approach gives ... blood an important measure of disease severity but ... , A research team from the Singapore-MIT Alliance for Research ...
(Date:8/29/2014)... some surprising discoveries about the body,s initial responses ... the team found that specialized cells in the ... viral invasion and are the source of gut ... (IL-1β). , Though aimed at the presence ... epithelium that provides a barrier to protect the ...
Breaking Biology News(10 mins):A new way to diagnose malaria 2A new way to diagnose malaria 3The early cost of HIV 2
... of Iowa study suggests there are two root causes of ... findings, which already have sparked a clinical trial, may guide ... patients with CF. Almost half of patients with ... quarter will develop it in their teens. In addition to ...
... a global life sciences technology company specializing in clinical ... latest version of iMedNet ™ ... is a ground-breaking eClinical solution that makes electronic data ... research initiative...even very small studies of short duration.  This ...
... HOUSTON -- (Sept. 17, 2012) -- In the largest ... research institutions are embarking upon a five-year National Institutes ... and more effective by uncovering the exact causes of ... is a life-giver, but hemoglobin can become deadly when ...
Cached Biology News:Cystic fibrosis disrupts pancreas two ways in CF-related diabetes 2Cystic fibrosis disrupts pancreas two ways in CF-related diabetes 3MedNet Solutions Announces Latest Enhancements To Its iMedNet EDC eClinical Solution 2Rice to take part in $10.8 million study of hemoglobin toxicity 2Rice to take part in $10.8 million study of hemoglobin toxicity 3
Purified anti-LAT...
Nuclear/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
Cytosol/Particulate Rapid Separation Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: 4C...
Request Info...
Biology Products: